Re: "A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: A randomized trial"

Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Small Cell Lung Carcinoma; Treatment Outcome; Cancer Research; Oncology